M. Clemons

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

Ian Judson, John Radford, Martin Harris et al. · European Journal of Cancer · 2001 · 391 citations

Medicine, Oncology, Pharmacology +12

Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

John R. Mackey, M. Clemons, Marc André Côté et al. · Current Oncology · 2008 · 143 citations · Full text

Medicine, Cardiology, Oncology +17

Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial

J. Baselga, S-A. Im, Hiroji Iwata et al. · Cancer Research · 2016 · 88 citations

Medicine, Oncology, Pharmacology +17

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Mario Campone, Seock‐Ah Im, Hiroji Iwata et al. · European Journal of Cancer · 2018 · 65 citations

Medicine, Oncology, Pharmacology +17

Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

Rebecca Dent, Geoffrey J. Lindeman, M. Clemons et al. · Journal of Clinical Oncology · 2010 · 63 citations

Medicine, Oncology, Pharmacology +15